Methadone

Pinnacle Treatment Centers Acquires MBA Wellness Center in Georgia

Retrieved on: 
Thursday, December 8, 2022
General Health, Mental Health, Alternative Medicine, Other Health, Health, Desert Hope Addiction Treatment Center, United States drug overdose death rates and totals over time, US Market Access Center, Georgia Department of Labor, Opioid use disorder, Medical statistics, Drug overdose, Fentanyl, Hospital, Wellness, Opioid, Patient, Stepping Stones Museum for Children, Peach, Disease, Medicaid, Methadone, Death, News, Public health, Passages Malibu, MAT, Gold, Health, Heroin, Corporate development, Georgia Department of Public Health, Medicare, Acquisition, Cereal, Pharmaceutical industry, Pinnacle, Atlanta

Pinnacle Treatment Centers , a leading provider of community-based drug and alcohol addiction treatment services, announced today it has acquired MBA Wellness Center in Stockbridge, Georgia.

Key Points: 
  • Pinnacle Treatment Centers , a leading provider of community-based drug and alcohol addiction treatment services, announced today it has acquired MBA Wellness Center in Stockbridge, Georgia.
  • Founded in 2010, MBA Wellness Center is a privately-owned, outpatient opioid addiction treatment program located approximately 20 miles south of Atlanta in Eagles Point Professional Building at 1233 Eagles Landing Parkway.
  • Pinnacle entered the Peach State in August 2020 when it purchased HealthQwest , an opioid addiction treatment provider with five locations.
  • MBA Wellness Center will take the HealthQwest name, and together, the six centers will help more than 1,300 patients every day overcome opioid use disorder.

Pinnacle Treatment Centers Opens Lacey Treatment Services in New Jersey to Provide Opioid Addiction Treatment

Retrieved on: 
Monday, December 5, 2022
Health, Mental Health, Other Health, Pinnacle, Desert Hope Addiction Treatment Center, Topical steroid withdrawal, Housing, United States drug overdose death rates and totals over time, Garden State, Suite, Opioid use disorder, Garden, Hospital, Health, Patient, Employment, Knowledge, Buprenorphine, FDA, Case management, Woman, Mental health, Medicaid, Methadone, Multimedia, Passages Malibu, MAT, Education, Heroin, Opioid, Chief

Pinnacle Treatment Centers , a leader in providing accessible, affordable care for people seeking treatment for opioid use disorder, has opened Lacey Treatment Services in New Jersey.

Key Points: 
  • Pinnacle Treatment Centers , a leader in providing accessible, affordable care for people seeking treatment for opioid use disorder, has opened Lacey Treatment Services in New Jersey.
  • Medicaid-friendly, Lacey Treatment Services will offer medication-assisted treatment (MAT) for adult men and women, including FDA-approved medicines such as methadone and buprenorphine, which curb withdrawal symptoms from heroin and opioid addiction; prevent relapse; and help ease the physical discomfort that accompanies opioid recovery.
  • Lacey Treatment Services treatment team is comprised of seasoned doctors, registered nurses, and credentialed clinical therapists who have all worked in medication-assisted treatment and bring a wealth of knowledge and experience to the team.
  • Pinnacles 11 addiction treatment centers in New Jersey include:
    Headquartered in Mount Laurel, New Jersey, Pinnacle Treatment Centers is a recognized leader in comprehensive drug and alcohol addiction treatment serving more than 35,000 patients daily in California, Georgia, Indiana, Kentucky, North Carolina, New Jersey, Ohio, Pennsylvania, and Virginia.

NASADAD and AATOD Release New Information about Patients Being Treated in Opioid Treatment Programs (OTPs)

Retrieved on: 
Monday, December 5, 2022
Opioid, Substance Abuse and Mental Health Services Administration, Opioid use disorder, ORN, American Association of Clinical Endocrinologists, National Association, State Alcohol and Tobacco Company of Iceland, Partnership, Patient, Mouding County, Treatment, Naltrexone, SAMHSA, Buprenorphine, Consultant, Methadone, Directory, Pharmaceutical industry, Substance Abuse, OTP

DC and NEW YORK, Dec. 5, 2022 /PRNewswire-PRWeb/ -- In order to capture current patient census data for people being treated for opioid use disorder in OTPs, the American Association for the Treatment of Opioid Dependence (AATOD) in partnership with the National Association of State Alcohol and Drug Abuse Directors (NASADAD), developed a census survey of all patients enrolled in treatment as of January 1, 2021, in Substance Abuse and Mental Health Service Administration (SAMHSA) certified OTPs in the United States (U.S.). The project was supported by the SAMHSA-funded Opioid Response Network (ORN).

Key Points: 
  • Of the 512,224 patients in OTPs who reported using MOUDs, 476,763 reported using methadone, 33,473 reported buprenorphine, and the remaining 1,988 reported using naltrexone.
  • Through this census, AATOD and NASADAD have captured crucial and actionable data to better understand treatment demand and demand for specific medications in OTPs.
  • ORN provides no costs education, training and consultation to enhance efforts addressing the opioid and stimulant use disorder crisis.
  • ORN has representation across the country to help others in applying locally relevant, evidence-based practices across harm reduction, prevention, treatment and recovery.

Ibogaine by David Dardashti Demonstrates Ongoing Success in Getting Users Off Suboxone, Methadone, and Fentanyl Without Requiring Short-Acting Opiates

Retrieved on: 
Thursday, November 24, 2022
Addiction, Depression, Life, Habit, ISBD, Happiness, Medical college, Buprenorphine, Pain, Physiology, International Society for Bipolar Disorders, Substance abuse, Medicine, Oxycodone, Subconscious, Trauma, Research, Panamerican University, Anxiety, Methadone, Ibogaine, Fear, Fentanyl, School, Mystery, Addictive Behaviors, Kabbalah, International Society of Sculptors, Painters and Gravers, Hospital, Pharmaceutical industry, Psychiatry, Affect (psychology), Talmud, Morphine

BOSTON, Nov. 23, 2022 /PRNewswire/ -- In the continuous fight against substance abuse across the continent, one ibogaine treatment center in Mexico has differentiated itself with proven protocols – designed to be tailored to individuals' unique needs – that have been shown to heal addiction and curb withdrawal.

Key Points: 
  • "The specific protocols we have been developing over 12 years have allowed us to see individuals respond extremely well long term to the ibogaine treatment."
  • Rabbi David Dardashti's facility is one of the only ibogaine facilities to publicly post direct and recent experiences from individuals who have experienced the treatment, in their own words.
  • Rabbi David Dardashti has dedicated his life to understanding the keys to human potential, happiness, and self-discovery.
  • Specializing in the study of Affective and Bipolar Disorders, her expertise is instrumental in helping people improve their lives.

Global Opioid Use Disorder Market Report to 2031 - Featuring Alkermes, AstraZeneca, BioDelivery Sciences International and Camurus Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 10, 2022
Health, Pharmaceutical, Codeine, Drug, OUD, Cardiovascular disease, Methadone, Fentanyl, Age, Opioid use disorder, Breast, Conditional sentence, Knee, Injection, Lung cancer, Incidence, Population, Buprenorphine, Porter's five forces analysis, Oxycodone, Neurological disorder, Cancer, World Cancer Research Fund International, Morphine, Joint, Self-control, Benchmarking, Distribution, Journal, Motivation, Patient, Pain, Breast cancer, Growth, Administration, Hydrocodone, JAMA Network Open, The New England Journal of Medicine, Opioid, Route of administration, Injury, CAGR, Pharmaceutical industry, Cereal, Dentistry, Retail

Opioid usage disorder (OUD) is a chronic, relapsing brain disorder that is characterized by obsessive opioid seeking and use despite negative effects.

Key Points: 
  • Opioid usage disorder (OUD) is a chronic, relapsing brain disorder that is characterized by obsessive opioid seeking and use despite negative effects.
  • Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the opioid use disorder market analysis from 2021 to 2031 to identify the prevailing opioid use disorder market opportunities.
  • The report includes the analysis of the regional as well as global opioid use disorder market trends, key players, market segments, application areas, and market growth strategies.

Acadia Healthcare Set to Open Four New Comprehensive Treatment Centers

Retrieved on: 
Tuesday, November 8, 2022
General Health, Health, Mental Health, Buprenorphine, Opioid addiction treatment in United States prisons, Patient, CTC, State, Health care, Chinese, The Sundays, Brand New, MAT, Acadia Healthcare, Heroin, Methadone, Dignity, Multimedia, Bed, Hospital, Pharmaceutical industry

Acadia Healthcare, a leading provider of behavioral healthcare services, is accepting new patients at its four new Comprehensive Treatment Centers (CTCs) in Georgia.

Key Points: 
  • Acadia Healthcare, a leading provider of behavioral healthcare services, is accepting new patients at its four new Comprehensive Treatment Centers (CTCs) in Georgia.
  • View the full release here: https://www.businesswire.com/news/home/20221107006188/en/
    Acadia recently acquired the four CTCs from Georgia-based Brand New Start Treatment Centers.
  • The four outpatient treatment centers, which are all located within 40 miles of Atlanta, are:
    We are excited to have the opportunity to play a critical role in ending the opioid epidemic in our community, said Erin McCarthy, regional vice president of Comprehensive Treatment Centers.
  • With more than 22,500 employees serving approximately 70,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Blood pressure, Yale School of Medicine, Central nervous system, Annual report, Initiative, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NIDA, Private Securities Litigation Reform Act, Research, Foundation, Food, NMDA, Form 10-K, Yale University, Human, Inc., HEAL, Connective tissue disease, Safety, Respiratory rate, Brain, Heart rate, APTX, Addictive behavior, National, Trial of the century, Nasdaq, Opioid, Post-traumatic stress disorder, Methadone, National Institute, Opioid use disorder, Buprenorphine, U.S. Securities and Exchange Commission, Oxycodone, Fast Track, Government budget balance, National Institute on Drug Abuse, Addiction, Rainforest Foundation Fund, OUD, Psychiatry, NIH, Drug, PTSD, Fentanyl, Patient, Naltrexone, Pharmacokinetics, Program, Pharmaceutical industry

NYX-783 is an NMDA receptor positive allosteric modulator also in Phase 2b development by Aptinyx for the treatment of post-traumatic stress disorder (PTSD).

Key Points: 
  • NYX-783 is an NMDA receptor positive allosteric modulator also in Phase 2b development by Aptinyx for the treatment of post-traumatic stress disorder (PTSD).
  • Additional preclinical research has demonstrated NYX-783s potential as a treatment option for the millions of people struggling with opioid use disorder.
  • We are pleased to continue our collaboration with Aptinyx for the evaluation of NYX-783 for the treatment of OUD, said Dr. DiLeone.
  • The company has multiple product candidates in clinical development in central nervous system indications, including cognitive impairment, post-traumatic stress disorder, and opioid use disorder.

Commercial insurance giving Kentuckians more access to medication-assisted treatment provider for substance use disorder

Retrieved on: 
Monday, October 17, 2022
Drug overdose, CDC, Insurance, Mental health, Joint Commission, OUD, Methadone, Opioid use disorder, United States Public Health Service, Family, SUD, CBH, OTP, Patient, Case management, Region, Medical statistics, Center, National Vital Statistics System, Medicare, National Center for Health Statistics, MAR, NVSS, BHG, Buprenorphine, National Center for Telehealth & Technology, UnitedHealth Group, Ageing, United States drug overdose death rates and totals over time, Fentanyl, GLOBE, Centers for Disease Control and Prevention, Topical steroid withdrawal, Naltrexone, Traffic, Death, FDA, Health insurance, Medicaid

Accepting appointments and walk-ins, CBH Treatment Centers are part of the nations largest Joint Commission-accredited network of outpatient treatment and recovery centers for substance use disorder (SUD).

Key Points: 
  • Accepting appointments and walk-ins, CBH Treatment Centers are part of the nations largest Joint Commission-accredited network of outpatient treatment and recovery centers for substance use disorder (SUD).
  • The Centers include both an outpatient treatment program (OTP) and an office-based opioid treatment program (OBOT) enabling prescription-based medications.
  • They offer all three FDA-approved medications for treating Opioid Use Disorder (OUD), which are methadone, buprenorphine, and naltrexone.
  • To learn more information about the CBH Kentucky treatment locations, visit the BHG web page or call toll-free 844-535-7291.

CODAC Behavioral Healthcare to Present at 2022 AATOD Conference

Retrieved on: 
Thursday, October 20, 2022
Linda, Rhode Island Department of Health, Time, Brown University School of Public Health, Risk, Government, Associate professor, Methadone, MAT, Public health, Conference, OTP, Prison, Patient, Opioid use disorder, RIDOC, Program, Drug, Ageing, Justice, Center of excellence, Treatment, MD, Doctor of Philosophy, Rhode Island Department of Corrections, Department, American Association, DO, Buprenorphine, Association, Research, Fentanyl, Comprehensive Model of Information Seeking, Success, Wisconsin Department of Justice, Opioid, MA, Death, Naltrexone, Center, SAMHSA, Health insurance, Management, Pharmaceutical industry, Corrections

· Tuesday, November 1, 2022 -- 1:30 PM - 3:00 PM Workshop: Patient Care & Best Practices 1 - Effectively Treating the Aging and Elderly in Opioid Treatment Programs: A Comprehensive Model Primary Presenter(s): Linda Hurley, MA CAGS, President and Chief Executive Officer, CODAC Co-Presenter(s): Andrew C. Stone, MD, Medical Director of CODAC Providence; Catherine DeGood, DO, Chief Medical Director for CODAC

Key Points: 
  • The theme of this national and international Conference is " The Power of Collaboration .
  • CODAC Behavioral Healthcare, a non-profit organization founded in 1971, is Rhode Island's oldest and largest provider of outpatient services for opioid use disorder, other substance use disorders, and concurrent behavioral health challenges.
  • With eight locations across Rhode Island, CODAC has attained Center of Excellence designations for each of its treatment sites.
  • For more information about CODAC, visit: http://www.codacinc.org
    The 2022 American Association for the Treatment of Opioid Dependence, Inc. (AATOD) Conference will be held in Baltimore, Maryland at the Baltimore Hilton Inner Harbor, October 30 - November 3, 2022.

Study Finds Video DOT Could Increase Access to Methadone Treatment and Reduce Risk

Retrieved on: 
Thursday, October 13, 2022
Other Health, Audio, Video, Pharmaceutical, Research, Insurance, Software, Mental Health, Hospitals, Professional Services, Science, Technology, Practice Management, Clinical Trials, Managed Care, Health, Apps, Applications, Health Technology, Health Insurance, National Institute, Infection, Medicaid, Hypertension, Substance Abuse, NIDA, Medicine, Observation, University of Washington School of Medicine, Sickle cell disease, COPD, Methadone, Smartphone, UW, Patient, Hospital, National Institute on Drug Abuse, Standard of care, Asthma, Opioid use disorder, College of Arts and Sciences, Multimedia, Hepatitis C, Technology, DOT, University, Directly observed treatment, short-course, Tuberculosis, National, Research, Journal of Substance Abuse Treatment, Diabetes, Journal, Counselor, Psychiatry, COVID-19, HCV, Pharmaceutical industry, Health

While DOT secures high rates of adherence, it also presents major barriers to access and increased risks.

Key Points: 
  • While DOT secures high rates of adherence, it also presents major barriers to access and increased risks.
  • But a new pilot study published in The Journal of Substance Abuse Treatment suggests that technology-enabled remote observation of methadone doses, using asynchronous video DOT, could allow opioid treatment programs to increase methadone adherence, reduce the barriers associated with in-person requirements, and help address the current behavioral health backlog.
  • For the study, the clinical pilot program took place over five months at three opioid treatment programs in Washington State.
  • By demonstrating the feasibility of video technology in the remote observation of methadone treatment, this study suggests that video DOT is a viable service model for methadone dosing observation that will provide greater treatment flexibility for patients and healthcare professionals.